Regorafenib and Nivolumab Simultaneous Combination Therapy (REGONIVO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03406871|
Recruitment Status : Completed
First Posted : January 23, 2018
Last Update Posted : April 26, 2021
Ono Pharmaceutical Co. Ltd
Bayer Yakuhin, Ltd.
Information provided by (Responsible Party):
Kohei Shitara, National Cancer Center Hospital East
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Actual Primary Completion Date :||October 23, 2019|
|Actual Study Completion Date :||November 26, 2020|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, Hirano N, Wakabayashi M, Nomura S, Sato A, Kuwata T, Togashi Y, Nishikawa H, Shitara K. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020 Jun 20;38(18):2053-2061. doi: 10.1200/JCO.19.03296. Epub 2020 Apr 28.